02.01. Área de Salud I Murcia Oeste

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study

Sun, 01 Nov 2026 00:00:00 GMT

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study Romero-Riquelme, Mónica-Alejandra; Aspas-Requena, Gaspar; Lloret-Madrid, Pilar; Gil, Cristina; Aguiar, Eliana; Tormo, Mar; del-Bernal-del-Castillo, Teresa; Rodríguez-Arboli, Eduardo; Serrano, Josefina; Sánchez-García, Joaquin; Rodríguez-Medina, Carlos; Mariz, José-Mario; Ayala, Rosa; Martínez-López, Joaquin; Amigo, María-Luz; Vives, Susana; Algarra-Algarra, Lorenzo; García-Boyero, Raimundo; Brioso, Joana; Castano, Tamara; Bergua-Burgues, Juan-Miguel; Salamero, Olga; Bass-Maturana, María-Francisca; Colorado, Mercedes; García-Fortes, María; Sayas-Lloris, María-José; Vicente, Belén-Vidriales; Chillon, Carmen; Pérez-Santaolalla, Esther; Madrigal, María-Dolores; Labrador-Gómez, Jorge; García-Pérez, María-José; Casado-Calderon, Soledad; Pérez-Encinas, Manuel; Balerdi-Malcorra, Amaia; Rodríguez, María-Sole; Gómez-García, Lara-María; Herrera-Puente, Pilar; Arce-Fernández, Olga; Barrios-García, Manuel; Noriega, Victor; Fernández, Rosa; Mateos, Mamen; Lacalzada, Carolina; Almela-Gallego, Agata; García-Garay, María-Carmen; Couto, Carmen; Pérez-Simon, José-Antonio; Barragan-González, Eva; Montesinos, Pau Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real-world data spanning the full adult age spectrum and including both FLT3-ITD and FLT3-TKD mutations remain limited. We retrospectively analyzed 1658 adults aged 14-85 years with newly diagnosed FLT3-mutated AML from 129 PETHEMA registry centers: 469 received IC + MIDO and 1189 IC alone. Composite complete remission was higher with IC + MIDO than IC (81.4% vs. 71.7%; p < 0.001) and Day 30 mortality was substantially lower (2.1% vs. 7.1%; p < 0.001). Median overall survival was 47.2 versus 19.3 months (HR 0.64; 95% CI, 0.53-0.76; p < 0.001), and the benefit was sustained after multivariable adjustment (HR 0.73; p = 0.017). In 261 propensity score-matched pairs, the effect was attenuated, remaining significant for event-free survival (HR 0.77; p = 0.029) and showing a nonsignificant trend for OS (HR 0.77; p = 0.06). Allogeneic hematopoietic stem cell transplantation in first remission was more frequent in the IC + MIDO cohort (48.9% vs. 41.3%; p = 0.023). Time-dependent analyses showed the largest MIDO effect among autologous and non-transplanted patients (OS HR 0.45; p = 0.138, and HR 0.69; p = 0.014, respectively). The benefit of MIDO was consistent irrespective of FLT3 mutation type, FLT3-ITD allelic burden, cytogenetic risk, and gender, while less improvement occurred among NPM1 wild type and secondary AML patients. This large real-world cohort confirms the survival benefit of MIDO plus IC across the full adult age spectrum, supporting its standard-of-care status in FLT3-mutated AML.

Cross-Cultural Adaptation and Psychometric Validation of the Hospital Survey on Patient Safety Culture Version 2 (HSOPSv2) in Spanish Hospitals

Sat, 01 Aug 2026 00:00:00 GMT

Cross-Cultural Adaptation and Psychometric Validation of the Hospital Survey on Patient Safety Culture Version 2 (HSOPSv2) in Spanish Hospitals López-Picazo-Ferrer, Julio-J; Torres-Ramírez, Juan; Gascón-Cánovas, Juan-J; Alcaraz-Martínez, Julián; Seva, Ana-M; Soria-Aledo, Víctor; Escolar, Pilar INTRODUCTION: Patient safety culture is a key component of healthcare quality. The Hospital Survey on Patient Safety Culture (HSOPS), developed by AHRQ in 2004, has been widely used internationally to assess healthcare professionals' perceptions of safety. In 2019, version 2 (HSOPSv2) was released, with improvements in structure and item clarity. Although a Spanish version for North America exists, it has not yet been validated in the Spanish hospital context. OBJECTIVES: To adapt and validate HSOPSv2 for the Spanish hospital context, ensuring its cultural, linguistic, and psychometric equivalence with the original version, and to assess its suitability for use in Spanish hospitals. METHODS: A cross-cultural adaptation process was conducted, including translation, back-translation, and expert consensus, followed by a cognitive pretest with 20 healthcare professionals. A pilot study was then carried out in four hospitals in Murcia and Alicante, with 369 participants. Internal consistency (Cronbach's ? and composite reliability), convergent validity (AVE, factor loadings), and discriminant validity (Fornell-Larcker criterion and HTMT) were assessed through confirmatory factor analysis using the WLSMV estimator. RESULTS: The 10-factor model showed satisfactory fit indices (CFI and TLI > 0.90; RMSEA < 0.06; SRMR < 0.08). Most dimensions presented acceptable reliability (? and CR > 0.70), except for "Staffing and Work Pace" and "Handoffs and Information Exchange." Convergent validity was adequate in seven of the ten dimensions (AVE ? 0.50), with some weaker loadings in negatively worded items. The Fornell-Larcker criterion indicated overlap in some communication-related constructs, although HTMT results supported overall discriminant validity. CONCLUSIONS: The Spanish version of HSOPSv2 shows satisfactory psychometric properties, comparable to other international adaptations. Its availability provides Spanish hospitals with a robust tool to assess patient safety culture, identify areas for improvement, and design interventions aimed at reducing adverse events and strengthening patient safety.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

Sun, 01 Nov 2026 00:00:00 GMT

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study Yague-Caballero, Carmen; García-López, Santiago; Royo-Esteban, Ana; Figueras-Panillo, Laura; Nos, Pilar; de-Castro, Luisa; Martin-Arranz, M-Dolores; Barreiro-de-Acosta, Manuel; Ricart, Elena; de-Francisco, Ruth; Iglesias, Eva; Giordano, Antonio; Varela, Pilar; Rodríguez-Lago, Iago; Rivero, Montserrat; Sicilia, Beatriz; Navarro-Llavat, Merce; Vera, Isabel; Suria, Carles; Guardiola, Jordi; Barrio, Jesus; Calafat, Margalida; Gutiérrez, Ana; Calvet, Xavier; de-la-Cruz, David-Rafael; Mesonero, Francisco; Martínez-Pascual, Cristina; Gisbert, Javier-P; Gargallo-Puyuelo, Carla-J; Monfort-I-Miquel, David; Sierra, Monica; Arranz, Laura; Rodríguez-Gutiérrez, Cristina; Lorente, Rufo; Bermejo, Fernando; Marquez-Mosquera, Lucía; Torres-Vicente, Gisela; Pérez-Calle, José-Lazaro; Huguet, José-M; Ramos, Laura; Ponferrada-Diaz, Angel; Ceballos, Daniel; Diz-Lois-Palomares, Ma-Teresa; Sese-Abizanda, Eva; Vega, Pablo; Pajares, Ramon; Santos-Fernández, Javier; Betore, Elena; Busquets, David; Merino, Olga; Martínez-Flores, Carlos; Zabana, Yamile; Sampedro-González, Manuela-Josefa; Ortiz-de-Zarate, Jone; Fuentes-Coronel, Ana; Sainz-Arnau, Empar; Carpio, Daniel; Jimenez, Nuria; Marin-Jimenez, Ignacio; Bujanda, Luis; Camargo-Camero, Raquel; Irabien, Martin; Abanades-Tercero, María; Velayos-Jimenez, Benito; Robledo-Andres, Pilar; Trapero, Ana-María; Delgado-Guillena, Pedro-G; Hernández-Villalba, Luis; Menacho, Margarita; Rull-Murillo, Nuria; Leal, Carles; Alba, Cristina; Gómez-Espín, Rosa; Lucendo, Alfredo-J; Van-Domselaar, Manuel; García-Alles, Laura; Iyo-Miyashiro, Eduardo; Crespo-Catala, Ana; Gilabert, Pau; Martin-Rodríguez, Daniel; Navas-López, Victor-Manuel; Calvo-Iniguez, María; Ginard, Daniel; Martínez-Pérez, Teresa; Domenech, Eugeni; Casas-Deza, Diego BACKGROUND: The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti-TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti-TNF treatment in this scenario. METHODS: Multicentre study based on data from the ENEIDA registry. Patients who received second-line anti-TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second-line anti-TNF after another anti-TNF and patients receiving first-line anti-TNF therapy. Treatment durability and short- and long-term clinical effectiveness were assessed. RESULTS: Sixty-six Crohn's disease patients and 117 UC patients receiving anti-TNF after other MOA were included. In CD, second-line anti-TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first-line anti-TNF therapy (HR 1.55; 95% CI, 1.05-2.30), without significant differences in short- or long-term clinical effectiveness. In UC, anti-TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first-line anti-TNF therapy (HR 1.69; 95% CI, 1.31-2.19) and with anti-TNF after another anti-TNF agent (HR 1.91; 95% CI, 1.48-2.48), its remission rates significantly lower at both short- and long-term follow-up (p < 0.001). CONCLUSIONS: Anti-TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first-line therapy or after another anti-TNF agent, especially in UC.

Variables Affecting Periprocedural Haemostatic Response in Patients With Haemophilia: Real-World Retrospective Study

Sat, 01 Aug 2026 00:00:00 GMT

Variables Affecting Periprocedural Haemostatic Response in Patients With Haemophilia: Real-World Retrospective Study Sánchez-Salas, José-Antonio; Soler-Espejo, Eva; García-Candel, Faustino; Roldán-Schilling, Vanessa